Drug Page

Review compares the effectiveness of pharmacological and non-pharmacological interventions for improving physical health outcomes in people diagnosed with schizophrenia.

Members of the U.S. Food and Drug Administration’s Psychiatry Products division go on the defensive in a new article, responding to concerns about the agency’s approval of digital aripiprazole.

University of Groningen researchers analyzed only small, short-term clinical trials of generally poor quality to determine that antipsychotics are not linked to increased risk of death in elderly people with dementia.

A new study demonstrates that the practice of mindfulness may ease pain in a way that is mechanistically distinct from the placebo effect. Research, published in the Journal of Neuroscience, found that mindfulness meditation not only outperformed placebo and fake meditation for pain relief but that it also activated different brain regions than the placebo treatments.

A new study, published in the American Journal of Physiology, investigates how the use of antidepressants during pregnancy can lead to a life-threatening lung...

An article published this month in the journal BMC Psychiatry suggests that there is a lack of efficacy for SSRIs and that they significantly increase the risk of serious side effects.

A new study published in Frontiers in Psychiatry concludes that “antidepressants are largely ineffective and potentially harmful.”

A recent review of the research found that benzodiazepine use may have long-term effects on memory and increase the risk for dementia. The study,...

Four different studies conducted in different ways examining different groups have linked use of certain psychiatric drugs to bone fracture risks and negative impacts on human bone development.

Researcher criticizes the many ways opposing viewpoints and dissenting voices are squashed in the field of medicine.

Researchers compared the efficacy of antidepressants using different rating scales and found them to be no different—just slightly better than placebo, and not meeting the criteria for clinical significance.

The October edition of the Journal of World Psychiatry, the 3rd ranked journal of Psychiatry, will publish a reanalysis of antidepressant efficacy versus placebo in major depression. When the researchers, Arif Khan and Walter Brown, analyzed the data from the FDA archives for antidepressants approved between 1985 and 1997, “it was evident that the conventional wisdom of 70% response with antidepressants was at best an overestimate.” In fact, “the magnitude of symptom reduction was about 40% with antidepressants,” compared to “about 30% with placebo.”

Not an Onion Study: SSRI antidepressants did consistently outperform placebo in clinical trials, researchers discovered, so long as 16 of the 17 questions about patients' feelings are ignored.

A new study explores how people manage to discontinue antipsychotic medication and examines how social supports may improve outcomes.

In exchange for pleading guilty to murder, a young soldier received a 45-year sentence with the possibility of parole. The plea resulted from evidence that Chantix, a smoking cessation drug manufactured by Pfizer, can increase hostility and agitation, according to the SunHerald. “Several experts provided some evidence that Chantix affected (the soldier’s) ability to appreciate the nature and quality or wrongfulness of his acts,” the SunHerald noted.

The odds of a child with Downs Syndrome being on a psychotropic medication increase steadily with age.

Dr. Yolande Lucire, a psychiatrist from Australia, recently published a paper about the iatrogenic effects of psychiatric drugs.

Amid growing criticism about the over-prescription of psychotropic medication in foster care, Pennsylvania commissioned PolicyLab to conduct an analysis of the use of psychiatric drugs among all of the state’s Medicaid-enrolled children. The report, released in June, found that the rate of psychotropic prescriptions among youth in Medicaid and foster care was higher than previously reported.

Organizations, advocates, scholars, and practitioners had a chance to give feedback regarding FDA processes.

Recent meta-analyses of antidepressant clinical trials have revealed that up to 82% of the effects associated with the drugs may be attributed to placebo and non-medication factors. A new study examined the attitudes of psychiatrists toward these non-pharmacologic factors and found a large discrepancy between their beliefs and the empirical evidence.